# The Column Group

> The Column Group is a San Francisco biotech venture firm that forms and finances drug-discovery companies, combining scientific advice with recruiting, operational support and follow-on capital. Its ecosystem includes platform and opportunity funds, the shared R&D model of TCG Labs Soleil, and operationally independent crossover investor TCGX.

- **Founded:** 2007
- **Headquarters:** San Francisco, United States
- **Founders:** Peter Svennilson (Founder and Managing Partner)
- **Products:** Platform funds, Opportunity funds, TCG Labs Soleil, TCG Crossover (TCGX), Portfolio operating support
- **Notable:** TCG reports 55 companies started or invested in, 18 exits and $4.0 billion in returns for its partners and portfolio; these are firm-reported cumulative figures., Portfolio company Aragon agreed to a Johnson & Johnson acquisition in 2013 for $650 million upfront plus up to $350 million in milestones., Genentech announced its agreement to acquire Seragon in July 2014.

## Products & services

- **Platform funds** — Create and finance drug-discovery companies with multiple-program potential; TCG describes three to four investments annually and typically $50-60 million or more invested per company.
- **Opportunity funds** — Flexible follow-on capital for selected portfolio companies in later development.
- **TCG Labs Soleil** — Dedicated venture funding paired with an evergreen research organization supporting independent single-asset drug companies.
- **TCG Crossover (TCGX)** — Operationally independent ecosystem firm investing in later-stage private and public drug-discovery companies.
- **Portfolio operating support** — Leadership and scientific recruitment, company formation, accounting support, scientific advice and board participation.
- **Swanson Fellowship** — One-year program focused on company creation and mentorship for aspiring biotech leaders.

## Achievements

- TCG reports 55 companies started or invested in, 18 exits and $4.0 billion in returns for its partners and portfolio; these are firm-reported cumulative figures.
- Portfolio company Aragon agreed to a Johnson & Johnson acquisition in 2013 for $650 million upfront plus up to $350 million in milestones.
- Genentech announced its agreement to acquire Seragon in July 2014.
- TCG Labs Soleil reported more than ten portfolio companies by July 2025.

## Latest updates

- **2026-10** — On October 19, portfolio company TriGemX Bio and TCGX Acquisition Corp. announced a proposed business combination; completion remained subject to closing conditions.
- **2025-07** — TCG Labs Soleil announced an additional $400 million, more than ten portfolio companies and an expanded R&D footprint including Shanghai.

## Links

- Website: https://www.thecolumngroup.com/
- LinkedIn: https://www.linkedin.com/company/the-column-group

---

Profile page: https://yespress.io/the-column-group
Published by YesPress — https://yespress.io
Last updated: 2026-10-27